GRAIL Past Earnings Performance

Past criteria checks 0/6

GRAIL's earnings have been declining at an average annual rate of -50.3%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 59.6% per year.

Key information

-50.3%

Earnings growth rate

-154.9%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate59.6%
Return on equity-107.0%
Net Margin-2,627.3%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How GRAIL makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:NL0 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24110-2,883373360
31 Mar 24100-1,491357354
31 Dec 2393-1,466345339
01 Jan 2356-5,399284330
02 Jan 2215-1,248234283
30 Jun 211-387172216
31 Mar 210-350148204
31 Dec 200-312124193
30 Sep 200-284113174
30 Jun 200-264105165
31 Mar 200-25497165
31 Dec 190-24589165

Quality Earnings: NL0 is currently unprofitable.

Growing Profit Margin: NL0 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NL0 is unprofitable, and losses have increased over the past 5 years at a rate of 50.3% per year.

Accelerating Growth: Unable to compare NL0's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NL0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).


Return on Equity

High ROE: NL0 has a negative Return on Equity (-106.98%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies